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neering of functional lymphoid tissues is challenging due to
the speciﬁc requirements for lymphoid differentiation and
has barely been accomplished to date. The aim of this study
was to develop a method for engineering of a T cell devel-
opment supporting 3D microenvironment and to assess if
implantation of such a tissue construct is feasible and results
in thymus-independent T cell development in vivo.
We fabricated 3D scaffolds using the FDA-approved
biodegradable polyester polycaprolactone (PCL) as well as
PCL/collagen composites. The scaffold architecture was
designed to provide mechanical and geometrical properties
necessary to support cell growth, proliferation,differentiation,
and motility. We utilized a layer-by-layer assembly approach
to fabricate structures that consisted of alternating thin
nanoﬁber layers and thick microﬁber layers (A, B). Nanoﬁber
layers were fabricated by electrospinning from a PCL/collagen
solution. These layers were functionalized by vascular endo-
thelial growth factor incorporation topromote vascularization
and seeded with OP9-DL1 stromal cells to provide Notch
signaling. Microﬁber layers were highly porous structures
fabricated from PCL by salt leaching, and were encapsulated
with a biomimetic dextran-based hydrogel containing in vitro
generated T lineage committed lymphoid precursor cells as
well as growth factors, cytokines and chemokines required for
T cell development (A, B). The layer-by-layer assembled
structurewith alternating layersof nanoﬁbers andmicroﬁbers
provided optimal support for stromal cell growth while facil-
itating angiogenesis and T lineage cell expansion and migra-
tion enabled by the highly porous microﬁber layers.
Subcutaneous implantation of layer-by-layer tissue
constructs into athymic nude mice resulted in rapid vascu-
larization. Implanted T lineage cells could be detected by in
vivo bioluminescence imaging at the implantation site (C) for
more than 1 month, and progeny of these cells efﬁciently
reconstituted secondary lymphoid organs of both allogeneic
and syngeneic recipients. Flow cytometric analysis of donor
cells in lymph nodes, spleen, and the implant 4 weeks after
implantation identiﬁed both CD4 and CD8 single positive T
cells as well as CD4 and CD8 double positive T cells and NKT
cells. The majority of T cells had an effector memory pheno-
type (but central memory and naïve cells were also present).We conclude that thymus-independent in vivo T cell
generation in a tissue-engineered artiﬁcial microenviron-
ment is feasible, and further development of this technology
is expected to produce an exciting innovative strategy for the
treatment of T cell deﬁciency.
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Injection of lymphoid organs such as the thymus in mice
is a valuable tool at the disposal of developmental biologists
and immunologists. In this study we performed for the ﬁrst
time freehand percutaneous ultrasound-guided intrathymic
injections in a variety of mouse models to develop novel
strategies promoting T cell immunity.
We found that in vitrogenerated T cell precursors can efﬁ-
ciently be delivered via injection into the thymus of a suble-
thally irradiated allogeneic recipient 3 h after irradiation, and
this procedure signiﬁcantly improved T cell reconstitution. As
expected, cell injection into the thymus of non-irradiated
syngeneic recipients resulted in low levels of thymic reconsti-
tution, indicating that in the absence of rejection the number of
availableniches forprecursor cells is still amajor limiting factor.
We next assessed if it was feasible to inject the thymus of mice
with signiﬁcantlydecreased thymicvolumesecondary toeither
age-related thymic involution or radiation-induced injury
(injection 24 h after irradiation). Even though challenging, we
were able to perform accurate injections of the target on both
settings, highlighting the potential of this approach for the
development of protocols to treat aging populations, as well as
for radiation countermeasure development.
We next studied the fate of intrathymically injected bone
marrow-derived progenitor cell populations including less
committed Lin-Sca-1+c-kit+ (LSK) cells and lymphoid-
primed multipotent progenitor cells. We found that espe-
cially LSK cells had excellent thymus-repopulating capacity
and their progeny almost exclusively committed to the T cell
lineage. Intrathymic injection of LSK cells into recipients of
a T-cell depleted BMT resulted in enhanced T cell reconsti-
tution on day +28.
We ﬁnally evaluated the efﬁcacy of 3 known thymopoietic
factors (interleukin 7 (IL-7), interleukin 22, keratinocyte
growth factor) when injected into the thymus before or after
irradiation. Only injection of IL-7, 3 h after irradiation resulted
in increased thymic cellularity on day +14. However, a single
injection of each of the 3 agents 24 h prior to irradiation
resulted in a 2 to 4-fold increase in thymus size by day +28.
In addition to the thymus, lymph nodes provide an even
easier, already clinically validated target. Importantly, lymph
nodes have been found to support extrathymic T cell devel-
opment during periods of lymphopenia. When T lineage
committed precursor cells were injected into single axillary
lymph nodes of irradiated nude mice, stable engraftment
was found and 4 weeks after injection, the majority of
recovered donor-derived cells were CD8+ T cells with
a central memory phenotype.
Our ﬁndings indicate that imaging-guided freehand
injection of lymphoid organs is feasible, safe, accurate, time
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avenues for cell, drug, and gene therapy.194
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Hematopoietic stem cell transplantation (HSCT) can
associated with T cell immunodeﬁciency which can
contribute to a high incidence of infections in patients. In the
thymus, hematopoietic progenitor cells undergo rapid
proliferation and differentiation to become mature T cells.
Factors which can affect the function of the thymus include:
age, high dose chemotherapy and radiotherapy, GVHD,
relapse and the occurrence of some opportunistic infections.
T cell rearrangement continues even in the elderly, and
because the TRECs are non-replicating episomal DNA and
their number can be decreased only by cell death, dilution
through cell division or both, the measurement of the
number of TRECs can be ameasure of immunity. The purpose
of this study was to measure T cell reconstitution after
hematopoietic stem cell transplantation in adult patients
with hematological malignancies by measuring TREC at
various time points after transplant.
To measure thymic output after HSCT, TREC levels were
measured in sixteen patients ages 23-68 (median age 53).
Two patients had CLL, one had follicular lymphoma and the
rest had acute leukemia (ten AML and three ALL). Ten
patients received myeloablative transplants and six received
reduced intensity transplants. All patients achieved full
donor chimerism at the time of analysis and all survived
aminimum of 6months after transplant (all but one survived
at least 500 days post-transplant). For the myeloablative
transplants, patients received 12 Gy of TBI followed by
a donor lymphocyte infusion of 2 x 108 CD3 cells/kg followed
two days later by cyclophosphamide at 60mg/kg/day for two
days followed one day later by a CD34 selected stem cell
product. For the non-myeloablative transplants, patients
received ﬂudarabine 30mg/m2 for four doses and cytarabine
2gm/m2 for four doses followed by 2 Gy of TBI then as
described for the myeloablative transplants. All patients
received tacrolimus and mycophenolate mofetil for GVHD
prophylaxis. The CD34 dose ranged from 1.40 - 5.89 x 106
cells/kg (median dose 3.34 x 106 cells/kg).
Peripheral blood samples were puriﬁed using the AUTO-
MACS magnetic cell sorter (Miltenyi Biotec). To determine
the purity of the CD4+ and CD8+ cells, two color cell staining
using ﬂuorochrome-conjugated antibodies against CD3+,
CD4+, CD8+ and CD56+ and ﬂow cytometry was performed.
TRECs were quantiﬁed by real-time polymerase chain reac-
tion (PCR) analysis using the 5’ nuclease (Taqman) assay. A
standard curve was plotted using samples with known
amounts of TREC, and TREC values for each sample was
calculated by the ABI7700 software. Samples were run and
analyzed in triplicate.Our analysis of the data showed that in general there
were more TREC's per 50,000 CD8 cells then CD4 cells.
Recipients with donors that had higher TRECs had more
TRECs after transplant and that with one exception the
number of TRECs in the recipient did not exceed that of the
donor.195
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Background: Reconstitution of the immune system
following allogeneic stem-cell transplantation (allo-SCT) is
a complex process that requires successful engraftment of
the hematopoietic stem cell, as well as adequate thymic
function. Although GVHD control, improvements in antibi-
otic spectra, and circumspection in the use of immunosup-
pressants have helped, too many patients still die of
infections because of insufﬁcient immunologic recovery.
Sirolimus has been used alone and in combination with
calcineurin inhibitors for prevention of allograft rejection
after solid organ transplantation. In the ﬁeld of hematopoi-
etic stem cell transplantation, the combination of sirolimus
and tacrolimus has also resulted in a low incidence of acute
GVHD and reduced transplant-related toxicity.
Methods: We evaluated the immune recovery status of
24 patients who received the combination of sirolimus
and tacrolimus as a GvHD prophylaxis compared to a
historical control (n¼21) using tacrolimus and methotre-
xate (MTX). They were conditioned with myeloablative
regimens.
Results: The incidence of acute GVHD in patients with siro-
limus based regimenwas lower. And the incidence of CMV or
EBV reactivation in the same group was higher. The recovery
of CD4+ Tcells and natural killer (NK) cells seemed to bemore
delayed in recipients with sirolimus based regimen
compared to those in patients with tacrolimus and MTX at 1
month after transplantation (8.8  1.6 vs 14.9  5.8 for CD4+
T cells, 35.7  6.4 vs 53.4  19.6 for NK cells). However, there
was no signiﬁcant difference between in the recovery of
CD4+T cells and NK cells at 3 months after transplantation. In
the aspect of humoral immunity, there was a trend to be
lower in immunoglobulin-A and Ig-M levels during 1 month
and 3months after transplantation in patients with sirolimus
based regimen. This difference was overcome around
post-transplant 6 months. And regulatory T cells
(CD4+CD25+Foxp3+) seemed to be higher in patients with
sirolimus based regimen.
Conclusion: The sirolimus based regimen is associated
with well-controlled acute GVHD. Although the correlation
between the increased risk of infection and delayed
immune reconstitution was not conﬁrmed, the regimen
might be cause of increasing the risk of opportunistic
infection. Therefore we need an effort of early tapering of
immunosuppressants and a careful monitoring for oppor-
tunistic infections in patients received sirolimus based
regimen.
